MAP2K7 and plexiform neurofibroma: Given the key role of abnormal RAF/MEK/ERK pathway signaling in neurofibromas, a phase I study of selumetinib (a MEK inhibitor) in children/young adults with NF1-related inoperable plexiform neurofibromas has demonstrated a median maximal decrease of 24% in the volume of the tumors [66].